Dr Reddy’s inks licensing pact with Gilead for Remdesivir to
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Dr Reddy's Laboratories said on 13 June, it has entered into a non-exclusive licensing agreement with Gilead Sciences Inc that will grant Dr Reddy's the right to register, manufacture and sell Gilead's investigational drug Remdesivir, a potential treatment for Covid-19 in 127 countries including India.

• Dr Reddy's will receive technology transfer from Gilead for manufacturing of this drug.

• Gilead Sciences has signed similar non-exclusive voluntary licensing agreements with Cipla, Hetero Labs, Jubilant Lifesciences, Mylan and Zydus Cadila.

• All these licenses are royalty-free until the World Health Organisation declares the world free from coronavirus pandemic, or a drug or vaccine is approved against the deadly virus.

• Remdesivir has received emergency use authorization by the US Food and Drug Administration (USFDA) to treat Covid-19.

• On June 1, the Drug Controller General of India (DCGI) granted the marketing authorization to Gilead Sciences' remdesivir injection 5 mg/mL and Remdesivir lyophilized powder for injection 100 mg.

Source: https://www.deccanchronicle.com/business/companies/140620/dr-reddys-inks-licensing-pact-with-gilead-sciences-for-remdesivir.html
Dr. T●●●●z H●●●●●●i and 4 others like this3 shares
Like
Comment
Share